Published in Proc Natl Acad Sci U S A on August 02, 2004
Fibroblast growth factor signals regulate a wave of Hedgehog activation that is essential for coronary vascular development. Genes Dev (2006) 2.56
Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J (2005) 1.89
The lymphatic system in health and disease. Lymphat Res Biol (2008) 1.78
Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev (2007) 1.76
Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci U S A (2005) 1.72
Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: a role for FGF signaling in lymphangiogenesis. Mol Biol Cell (2005) 1.62
Deletion of tetraspanin Cd151 results in decreased pathologic angiogenesis in vivo and in vitro. Blood (2006) 1.53
First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer (2006) 1.53
Ocular lymphatics: state-of-the-art review. Lymphology (2009) 1.52
Mechanisms of lymphatic metastasis. J Clin Invest (2014) 1.46
Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog Retin Eye Res (2010) 1.33
Lymphangiogenic factors, mechanisms, and applications. J Clin Invest (2014) 1.27
Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol (2015) 1.24
PPARalpha deficiency in inflammatory cells suppresses tumor growth. PLoS One (2007) 1.24
Lymphangiogenesis and angiogenesis: concurrence and/or dependence? Studies in inbred mouse strains. FASEB J (2009) 1.18
Corneal transparency: genesis, maintenance and dysfunction. Brain Res Bull (2009) 1.18
Differential distribution of blood and lymphatic vessels in the murine cornea. Invest Ophthalmol Vis Sci (2009) 1.17
Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: role of nuclear factor-kappaB-activated stromal cells in inflammatory angiogenesis. Am J Pathol (2007) 1.16
Lymphangiogenesis and cancer. Genes Cancer (2011) 1.16
Lymphangiogenesis: a new player in cancer progression. World J Gastroenterol (2010) 1.15
Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis. Cancer Res (2009) 1.13
Blood vessel endothelial VEGFR-2 delays lymphangiogenesis: an endogenous trapping mechanism links lymph- and angiogenesis. Blood (2010) 1.09
Contribution of bone marrow-derived pericyte precursor cells to corneal vasculogenesis. Invest Ophthalmol Vis Sci (2005) 1.08
Developmental and pathological lymphangiogenesis: from models to human disease. Histochem Cell Biol (2008) 1.07
Lymphangiogenesis and lymphatic remodeling induced by filarial parasites: implications for pathogenesis. PLoS Pathog (2009) 1.07
Experimental models to study lymphatic and blood vascular metastasis. J Surg Oncol (2011) 1.07
Endogenous angiogenesis inhibitor vasohibin1 exhibits broad-spectrum antilymphangiogenic activity and suppresses lymph node metastasis. Am J Pathol (2010) 1.06
Macrophage-mediated lymphangiogenesis: the emerging role of macrophages as lymphatic endothelial progenitors. Cancers (Basel) (2012) 1.06
Slit-Robo signaling mediates lymphangiogenesis and promotes tumor lymphatic metastasis. Biochem Biophys Res Commun (2010) 1.06
Regulation of blood vessel versus lymphatic vessel growth in the cornea. Invest Ophthalmol Vis Sci (2008) 1.05
Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells. PLoS One (2010) 1.03
Rapamycin inhibits lymphatic endothelial cell tube formation by downregulating vascular endothelial growth factor receptor 3 protein expression. Neoplasia (2012) 0.98
Tumor lymphangiogenesis as a potential therapeutic target. J Oncol (2012) 0.97
Lymphedema and therapeutic lymphangiogenesis. Biomed Res Int (2013) 0.97
Development of the endothelium: an emphasis on heterogeneity. Semin Thromb Hemost (2010) 0.94
Growth hormone promotes lymphangiogenesis. Am J Pathol (2008) 0.92
Potential therapeutic strategies for lymphatic metastasis. Microvasc Res (2007) 0.92
Lymphangiogenesis in myocardial remodelling after infarction. Histopathology (2007) 0.91
Lymphatics in lymphangioleiomyomatosis and idiopathic pulmonary fibrosis. Eur Respir Rev (2012) 0.90
Lymphatics and lymphangiogenesis in the eye. J Ophthalmol (2012) 0.89
In vitro assays using primary embryonic mouse lymphatic endothelial cells uncover key roles for FGFR1 signalling in lymphangiogenesis. PLoS One (2012) 0.88
Apelin promotes lymphangiogenesis and lymph node metastasis. Oncotarget (2014) 0.86
Interplay between Inflammatory Responses and Lymphatic Vessels. Immune Netw (2014) 0.85
An overview of lymphatic vessels and their emerging role in cardiovascular disease. J Cardiovasc Dis Res (2011) 0.85
Lysophosphatidic acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells. Am J Pathol (2012) 0.85
Lymphatic vascular response to acute inflammation. PLoS One (2013) 0.84
RASSF8 downregulation promotes lymphangiogenesis and metastasis in esophageal squamous cell carcinoma. Oncotarget (2015) 0.84
b-FGF induces corneal blood and lymphatic vessel growth in a spatially distinct pattern. Cornea (2012) 0.83
Therapeutic lymphangiogenesis with implantation of adipose-derived regenerative cells. J Am Heart Assoc (2012) 0.83
Lymphatic endothelial heparan sulfate deficiency results in altered growth responses to vascular endothelial growth factor-C (VEGF-C). J Biol Chem (2011) 0.83
VEGF Trap(R1R2) suppresses experimental corneal angiogenesis. Eur J Ophthalmol (2010) 0.81
Sphingosine-1-phosphate induces VEGF-C expression through a MMP-2/FGF-1/FGFR-1-dependent pathway in endothelial cells in vitro. Acta Pharmacol Sin (2013) 0.81
Molecular pathways of lymphangiogenesis and lymph node metastasis in head and neck cancer. Eur Arch Otorhinolaryngol (2011) 0.80
Lymphatics in idiopathic pulmonary fibrosis: new insights into an old disease. Lymphat Res Biol (2009) 0.79
Features of corneal neovascularization and lymphangiogenesis induced by different etiological factors in mice. Graefes Arch Clin Exp Ophthalmol (2010) 0.78
(Lymph)angiogenic influences on hematopoietic cells in acute myeloid leukemia. Exp Mol Med (2014) 0.78
Adiponectin-mediated modulation of lymphatic vessel formation and lymphedema. J Am Heart Assoc (2013) 0.78
Impact of the prolymphangiogenic crosstalk in the tumor microenvironment on lymphatic cancer metastasis. Biomed Res Int (2014) 0.77
CXCL12/CXCR4 axis regulates neovascularization and lymphangiogenesis in sutured corneas in mice. Mol Med Rep (2016) 0.77
The Antitumor Effect of Gekko Sulfated Glycopeptide by Inhibiting bFGF-Induced Lymphangiogenesis. Biomed Res Int (2016) 0.77
Tissue engineering and regeneration of lymphatic structures. Future Oncol (2013) 0.77
Advances in the research on lymphangiogenesis in carcinoma tissues (Review). Oncol Lett (2010) 0.77
Lamstatin--a novel inhibitor of lymphangiogenesis derived from collagen IV. J Cell Mol Med (2012) 0.77
Tube-like structures with co-expression of D2-40 and CD34: newly formed vasculatures? Int J Biol Sci (2012) 0.76
The corneal micropocket assay: a model of angiogenesis in the mouse eye. J Vis Exp (2014) 0.76
Fibroblast growth factor-2 drives and maintains progressive corneal neovascularization following HSV-1 infection. Mucosal Immunol (2017) 0.76
Construction of a disulfide-stabilized diabody against fibroblast growth factor-2 and the inhibition activity in targeting breast cancer. Cancer Sci (2016) 0.75
Lymphatic system anomalies in Crouzon syndrome. BMJ Case Rep (2009) 0.75
Hypoxic conditioned medium from mesenchymal stem cells promotes lymphangiogenesis by regulation of mitochondrial-related proteins. Stem Cell Res Ther (2016) 0.75
Topical bFGF Improves Secondary Lymphedema through Lymphangiogenesis in a Rat Tail Model. Plast Reconstr Surg Glob Open (2014) 0.75
Limited versus total epithelial debridement ocular surface injury: Live fluorescence imaging of hemangiogenesis and lymphangiogenesis in Prox1-GFP/Flk1::Myr-mCherry mice. Biochim Biophys Acta (2016) 0.75
Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib. Drug Des Devel Ther (2017) 0.75
Fluid pressure is a magnitude-dependent modulator of early endothelial tubulogenic activity: implications related to a potential tissue-engineering control parameter. Tissue Eng Part A (2012) 0.75
Molecular underpinnings of corneal angiogenesis: advances over the past decade. Int J Ophthalmol (2016) 0.75
Model of Vascular Desmoplastic Multispecies Tumor Growth. J Theor Biol (2017) 0.75
Cutaneous wound healing. N Engl J Med (1999) 19.12
Genes expressed in human tumor endothelium. Science (2000) 10.75
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med (2001) 7.78
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (1992) 7.49
Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A (1995) 7.11
Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science (1997) 6.37
VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest (2004) 5.59
A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J (1996) 5.33
Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol (1999) 5.02
Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol (2002) 4.66
Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A (1998) 4.48
Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J (1997) 4.07
Universal GFP reporter for the study of vascular development. Genesis (2000) 3.97
The leukocyte common antigen family. Annu Rev Immunol (1989) 3.78
Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A (1998) 3.72
Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet (2000) 3.66
Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest (2004) 3.53
A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci (1996) 3.49
Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol (1998) 3.12
Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol (2001) 3.00
Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J (2001) 3.00
Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci U S A (2001) 2.81
Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J (2002) 2.74
Molecular characterization of lymphatic endothelial cells. Proc Natl Acad Sci U S A (2002) 2.68
Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res (1998) 2.60
VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol (1997) 2.43
Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci U S A (2002) 2.30
VEGFs, receptors and angiogenesis. Semin Cancer Biol (1999) 2.25
Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol (2000) 2.24
Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. Invest Ophthalmol Vis Sci (2002) 1.82
Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res (2004) 1.74
Heparan sulfate mediates bFGF transport through basement membrane by diffusion with rapid reversible binding. J Biol Chem (1999) 1.70
Transport in lymphatic capillaries. I. Macroscopic measurements using residence time distribution theory. Am J Physiol (1996) 1.63
Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res (2001) 1.55
The specificity of receptor binding by vascular endothelial growth factor-d is different in mouse and man. J Biol Chem (2001) 1.55
The regulatory effects of cytokines on lymphatic angiogenesis. Lymphology (1997) 1.51
c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc Natl Acad Sci U S A (1999) 1.49
Lymphangiogenic gene therapy with minimal blood vascular side effects. J Exp Med (2002) 1.29
Basic fibroblast growth factor binds its receptors, is internalized, and stimulates DNA synthesis in Balb/c3T3 cells in the absence of heparan sulfate. J Biol Chem (1996) 1.12
Synthesis of stromal glycosaminoglycans in response to injury. J Cell Biochem (1995) 0.94
Vascular endothelial growth factor-D expression in human atherosclerotic lesions. Cardiovasc Res (2003) 0.93
Embryonic lymphangiogenesis. Cell Tissue Res (1999) 0.85
Lymphatic and blood vasculature of the forming corpus luteum. Lymphology (1987) 0.81
Investigations on the uterine lymphatics of juvenile mice, up to the onset of sexual maturity. Lymphology (1978) 0.79
"Stemness": transcriptional profiling of embryonic and adult stem cells. Science (2002) 15.55
Engineering vascularized skeletal muscle tissue. Nat Biotechnol (2005) 7.73
Clinical translation of angiogenesis inhibitors. Nat Rev Cancer (2002) 6.58
TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc Natl Acad Sci U S A (2004) 4.60
A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst (2006) 4.44
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature (2009) 3.93
Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst (2002) 3.77
Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol (2009) 3.55
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res (2007) 3.53
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (2010) 3.43
Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood (2007) 3.38
Unexpectedly efficient homing capacity of purified murine hematopoietic stem cells. Immunity (2004) 3.35
Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle (2006) 3.10
Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A (2003) 3.10
Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. J Clin Invest (2011) 2.99
VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med (2006) 2.67
Exogenous control of mammalian gene expression through modulation of RNA self-cleavage. Nature (2004) 2.48
Endothelial protein C receptor (CD201) explicitly identifies hematopoietic stem cells in murine bone marrow. Blood (2005) 2.48
Platelets actively sequester angiogenesis regulators. Blood (2008) 2.47
PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest (2002) 2.31
Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation (2003) 2.27
Failure of bone marrow to reconstitute lung epithelium. Am J Respir Cell Mol Biol (2005) 2.26
Complete correction of murine Artemis immunodeficiency by lentiviral vector-mediated gene transfer. Proc Natl Acad Sci U S A (2006) 2.17
Notch signaling regulates platelet-derived growth factor receptor-beta expression in vascular smooth muscle cells. Circ Res (2008) 2.15
The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res (2005) 2.14
A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol (2005) 2.14
Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol (2002) 2.10
Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature (2008) 2.09
Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci U S A (2006) 2.09
Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci U S A (2009) 2.08
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res (2009) 2.04
Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest (2004) 2.03
Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation. Mol Ther (2005) 1.99
Endostatin's antiangiogenic signaling network. Mol Cell (2004) 1.95
Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol (2008) 1.93
Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res (2009) 1.90
Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A (2006) 1.89
Maternal preeclampsia predicts the development of bronchopulmonary dysplasia. J Pediatr (2009) 1.89
Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci U S A (2007) 1.85
Stem cell therapies benefit Alport syndrome. J Am Soc Nephrol (2009) 1.83
Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood (2010) 1.81
PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A (2008) 1.80
Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest (2011) 1.74
Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics (2005) 1.72
Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res (2008) 1.72
Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med (2004) 1.70
Gene therapy of prostate cancer with the soluble vascular endothelial growth factor receptor Flk1. Cancer Biol Ther (2002) 1.67
Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol (2012) 1.60
Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics (2006) 1.60
Making the cut: protease-mediated regulation of angiogenesis. Exp Cell Res (2006) 1.59
Blue rubber bleb nevus syndrome: surgical eradication of gastrointestinal bleeding. Ann Surg (2005) 1.59
Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins. Blood (2009) 1.57
Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat (2010) 1.57
Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res (2008) 1.54
Deletion of tetraspanin Cd151 results in decreased pathologic angiogenesis in vivo and in vitro. Blood (2006) 1.53
Forty-year journey of angiogenesis translational research. Sci Transl Med (2011) 1.51
ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem (2004) 1.51
Recombinant adeno-associated virus type 2 pseudotypes: comparing safety, specificity, and transduction efficiency in the primate striatum. Laboratory investigation. J Neurosurg (2010) 1.50
Endogenous angiogenesis inhibitors prevent adaptive capillary growth in left ventricular pressure overload hypertrophy. Ann Thorac Surg (2012) 1.49
Large-scale identification of Legionella pneumophila Dot/Icm substrates that modulate host cell vesicle trafficking pathways. Cell Microbiol (2008) 1.47
Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Mol Cancer Ther (2008) 1.47
Doxycycline induces membrane expression of VE-cadherin on endothelial cells and prevents vascular hyperpermeability. FASEB J (2008) 1.46
Heparan sulfation-dependent fibroblast growth factor signaling maintains embryonic stem cells primed for differentiation in a heterogeneous state. Stem Cells (2010) 1.44
Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res (2007) 1.44
Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients. Breast Cancer Res (2004) 1.42
Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med (2006) 1.42
Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor. J Biol Chem (2003) 1.41
Genetically engineered T cells to target EGFRvIII expressing glioblastoma. J Neurooncol (2009) 1.40
The rationale for nonsteroidal anti-inflammatory drug therapy for inflammatory myofibroblastic tumors: a Children's Oncology Group study. J Pediatr Surg (2005) 1.39
Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clin Exp Metastasis (2008) 1.38
International Health Links movement expands in the United Kingdom. Int Health (2010) 1.38
Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell (2005) 1.37
Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Rev (2010) 1.36
Endothelial-directed hepatic regeneration after partial hepatectomy. Ann Surg (2003) 1.34
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol (2007) 1.34
Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res (2005) 1.33
Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res (2005) 1.33
Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res (2005) 1.33
VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res (2009) 1.32
Microdeformational wound therapy: effects on angiogenesis and matrix metalloproteinases in chronic wounds of 3 debilitated patients. Ann Plast Surg (2006) 1.30
Exogenous control of mammalian gene expression via modulation of translational termination. Nat Med (2006) 1.30
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest (2013) 1.30
Mitotic spindle destabilization and genomic instability in Shwachman-Diamond syndrome. J Clin Invest (2008) 1.29
Evidence by molecular profiling for a placental origin of infantile hemangioma. Proc Natl Acad Sci U S A (2005) 1.28
PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther (2005) 1.28
Platelet-associated PF-4 as a biomarker of early tumor growth. Blood (2007) 1.26